Can FIB4 and NAFLD fibrosis scores help endocrinologists refer patients with non-alcoholic fat liver disease to a hepatologist?

Archives of Endocrinology and Metabolism

Volumn 61, Issue 3, 2017, Pages 276-281

  Nones, Rodrigo Bremer ^a   Ivantes, Cláudia Pontes ^a   Pedroso, Maria Lucia Alves ^b  

^a HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

^b FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Liver fibrosis; Mathematical model; NAFLD; Nonalcoholic steatohepatitis; Specialist

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

BIOPSY; BLOOD; DISEASE COURSE; ENDOCRINOLOGIST; EVALUATION STUDY; FEMALE; GASTROENTEROLOGIST; HUMAN; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PATHOLOGY; PATIENT REFERRAL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STANDARD; THEORETICAL MODEL;

ALANINE TRANSAMINASE; ASPARTATE AMINOTRANSFERASES; BIOPSY; DISEASE PROGRESSION; ENDOCRINOLOGISTS; FEMALE; GASTROENTEROLOGISTS; HUMANS; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, THEORETICAL; NON-ALCOHOLIC FATTY LIVER DISEASE; REFERENCE STANDARDS; REFERRAL AND CONSULTATION; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 85024481214     PISSN: 23593997     EISSN: 23594292     Source Type: Journal    
DOI: 10.1590/2359-3997000000233     Document Type: Article

References (44)

1. Wree A, Kahraman A, Gerken G, Canbay A. Obesity affects the liver-the link between adipocytes and hepatocytes. Digestion. 2011;83(1-2):124-33.
2. Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis. 2010;28(1):155-61.
3. Cotrim HP, Parise ER, Oliveira CP, Leite N, Martinelli A, Galizzi J. S, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol. 2011;10(1):33-7.
4. IBGE. POF 2008-2009-Antropometria e estado nutricional de crianças, adolescentes e adultos no Brasil. Comunicação Social do Instituto Brasileiro de Geografia e Estatística. Available at: http://www.ibge.gov.br/home/presidencia/noticias/noticia_visualiza.php?id_noticia=1699andid_pagina=1. Published 2010. Accessed on: Mar. 11, 2012.
5. Lonardo A, Lombardini S, Ricchi M, Scaglioni F, Loria P. Review article: hepatic steatosis and insulin resistance. Aliment Pharmacol Ther. 2005;22 Suppl 2:64-70.
6. Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23(1):72-82.
7. Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53(2):372-84.
8. Preiss D, Sattar N. Non-alcoholic fatty liver disease: an overview of prevalence, diagnosis, pathogenesis and treatment considerations. Clin Sci (Lond). 2008;115(5):141-50.
9. Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7(4):195-203.
10. Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management. Hepatology. 2009;49(1):306-17.
11. Bayard M, Holt J, Boroughs E. Nonalcoholic fatty liver disease. Am Fam Physician. 2006;73(11):1961-8.
12. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006;43(2 Suppl 1):S99-112.
13. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
14. Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(42):15539-48.
15. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and noninvasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2014;20(2):475-85.
16. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33(5):525-40.
17. Clark PJ, Patel K. Noninvasive tools to assess liver disease. Curr Opin Gastroenterol. 2011;27(3):210-6.
18. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35 Suppl 1:S64-71.
19. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-97.
20. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26.
21. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology. 2007;46(1):32-6.
22. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36(4 Pt 1):986-92.
23. Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54.
24. Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes (Lond). 2010;34(10):1451-67.
25. Hu KC, Wang HY, Liu SC, Liu CC, Hung CL, Bair MJ, et al. Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease. World J Gastroenterol. 2014;20(24):7718-29.
26. Arulanandan A, Ang B, Bettencourt R, Hooker J, Behling C, Lin GY, et al. Association Between Quantity of Liver Fat and Cardiovascular Risk in Patients With Nonalcoholic Fatty Liver Disease Independent of Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2015;13(8):1513-20.e1.
27. Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617-49.
28. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology. 2010;51(5):1820-32.
29. Sun B, Karin M. Obesity, inflammation, and liver cancer. J Hepatol. 2012;56(3):704-13.
30. Byrne CD, Olufadi R, Bruce KD, Cagampang FR, Ahmed MH. Metabolic disturbances in non-alcoholic fatty liver disease. Clin Sci (Lond). 2009;116(7):539-64.
31. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-12.
32. Estep JM, Birerdinc A, Younossi Z. Non-invasive diagnostic tests for non-alcoholic fatty liver disease. Curr Mol Med. 2010;10(2):166-72.
33. Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24(5):695-708.
34. Lembrança L, Medina J, Portugal M, Almeida D, Solla J, Gadelha R, et al. Epidemiological assessment of liver disease in northeastern Brazil by means of a standardized liver biopsy protocol. Ann Hepatol. 2011;10(1):43-9.
35. Uslusoy HS, Nak SG, Gülten M. Noninvasive predictors for liver fibrosis in patients with nonalcoholic steatohepatitis. World J Hepatol. 2011;3(8):219-27.
36. Uslusoy HS. Non-alcoholic steatohepatitis with normal aminotransferase values. World J Gastroenterol. 2009;15(15):1863-8.
37. Fierbinteanu-Braticevici C. Noninvasive investigations for non alcoholic fatty liver disease and liver fibrosis. World J Gastroenterol. 2010;16(38):4784-91.
38. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913-24.
39. Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12(1):2.
40. Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, et al. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. J Gastroenterol. 2013;48(9):1051-60.
41. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ; Nash Clinical Research Network. Use of the Fib4 Index for Non-Invasive Evaluation of Fibrosis in Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2009;7(10):1104-12.
42. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265-9.
43. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26(10):1536-43.
44. Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. Curr Opin Gastroenterol. 2010;26(3):202-8.